Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation
Executive Summary
House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
You may also be interested in...
Democrats’ New Wave Leads Attack On Pharma At Drug Pricing Hearing
The last quarter of the four-hour hearing may be a warning of things to come for pharma if the newer guard of Democrats keeps gaining traction among voters and power in Congress.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.
'Like Water': Pharma Avoids Much Scrutiny In Messy Presidential Debate
Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: